Survival of the fittest: Metabolic adaptations in cancer

Current Opinion in Genetics and Development

Volumn 21, Issue 1, 2011, Pages 59-66

  Berardi, Marcelo J ^a   Fantin, Valeria R ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b AGIOS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID; GLUCOSE; GLUTAMINE;

CANCER CELL; CANCER GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; EVOLUTIONARY ADAPTATION; GENE ACTIVATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MITOCHONDRION; NONHUMAN; ONCOGENE; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

ADAPTATION, BIOLOGICAL; ANIMALS; CELL PROLIFERATION; GLUCOSE; GLUTAMINE; HUMANS; MITOCHONDRIA; NEOPLASMS;

EID: 79551646672     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2010.10.001     Document Type: Review

References (67)

1. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet 1993, 9:138-141.
2. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
3. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
4. Frezza C., Tennant D.A., Gottlieb E. IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 2010, 17:7-9.
5. Thompson C.B. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009, 360:813-815.
6. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
7. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
8. Gillies R.J., Robey I., Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008, 49(Suppl. 2):24S-42S.
9. Warburg O. The Metabolism of Tumors 1930, Arnold Constable, London.
10. Semenza GL: HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010, 20:51-56.
11. King A., Selak M.A., Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006, 25:4675-4682.
12. Kaelin W.G. SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling. Cancer Cell 2009, 16:180-182.
13. Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., Dalla-Favera R., Dang C.V. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997, 94:6658-6663.
14. Fantin V.R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434.
15. Xie H., Valera V.A., Merino M.J., Amato A.M., Signoretti S., Linehan W.M., Sukhatme V.P., Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 2009, 8:626-635.
16. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang CV: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010, 107:2037-2042.
17. Kim J.W., Gao P., Liu Y.C., Semenza G.L., Dang C.V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007, 27:7381-7393.
18. Osthus R.C., Shim H., Kim S., Li Q., Reddy R., Mukherjee M., Xu Y., Wonsey D., Lee L.A., Dang C.V. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000, 275:21797-21800.
19. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
20. David CJ, Chen M, Assanah M, Canoll P, Manley JL: HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
21. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., Gottlieb E., Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
22. Kondoh H., Lleonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005, 65:177-185.
23. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F. Hwang PM: p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
24. Pastorino J.G., Hoek J.B., Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 2005, 65:10545-10554.
25. Rathmell J.C., Fox C.J., Plas D.R., Hammerman P.S., Cinalli R.M., Thompson C.B. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003, 23:7315-7328.
26. Brand K.A., Hermfisse U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J 1997, 11:388-395.
27. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7:763-777.
28. Medes G., Thomas A., Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953, 13:27-29.
29. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
30. Wellen K.E., Hatzivassiliou G., Sachdeva U.M., Bui T.V., Cross J.R., Thompson C.B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009, 324:1076-1080.
31. Chiche J, Brahimi-Horn MC, Pouyssegur J: Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 2010, 14:771-794.
32. Shimoda L.A., Fallon M., Pisarcik S., Wang J., Semenza G.L. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 2006, 291:L941-949.
33. Ullah M.S., Davies A.J., Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006, 281:9030-9037.
34. Izumi H., Torigoe T., Ishiguchi H., Uramoto H., Yoshida Y., Tanabe M., Ise T., Murakami T., Yoshida T., Nomoto M., et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003, 29:541-549.
35. Wise DR, Thompson CB: Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35:427-433.
36. Yuneva M., Zamboni N., Oefner P., Sachidanandam R., Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007, 178:93-105.
37. Yuneva M. Finding an "Achilles' heel" of cancer: the role of glucose and glutamine metabolism in the survival of transformed cells. Cell Cycle 2008, 7:2083-2089.
38. Morrish F., Neretti N., Sedivy J.M., Hockenbery D.M. The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 2008, 7:1054-1066.
39. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008, 105:18782-18787.
40. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
41. Abou-Khalil W.H., Yunis A.A., Abou-Khalil S. Prominent glutamine oxidation activity in mitochondria of hematopoietic tumors. Cancer Res 1983, 43:1990-1993.
42. DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., Thompson C.B. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007, 104:19345-19350.
43. Galluzzi L., Morselli E., Kepp O., Vitale I., Rigoni A., Vacchelli E., Michaud M., Zischka H., Castedo M., Kroemer G Mitochondrial gateways to cancer. Mol Aspects Med 2010, 31:1-20.
44. Fantin V.R., Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 2006, 25:4787-4797.
45. Hockenbery DM: Targeting mitochondria for cancer therapy. Environ Mol Mutagen, 51:476-489.
46. Rolfe D.F., Brown G.C. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 1997, 77:731-758.
47. Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 1961, 191:144-148.
48. Brand K. Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr 1997, 29:355-364.
49. Chen L.B. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 1988, 4:155-181.
50. Heerdt B.G., Houston M.A., Augenlicht L.H. Growth properties of colonic tumor cells are a function of the intrinsic mitochondrial membrane potential. Cancer Res 2006, 66:1591-1596.
51. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, et al.: Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010, 2:31ra34.
52. Samudio I., Fiegl M., Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 2009, 69:2163-2166.
53. Derdak Z., Mark N.M., Beldi G., Robson S.C., Wands J.R., Baffy G. The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res 2008, 68:2813-2819.
54. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., van der Mey A., Taschner P.E., Rubinstein W.S., Myers E.N., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-851.
55. Brandon M., Baldi P., Wallace D.C. Mitochondrial mutations in cancer. Oncogene 2006, 25:4647-4662.
56. Tomlinson I.P., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E., Kelsell D., Leigh I., Gorman P., Lamlum H., Rahman S., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30:406-410.
57. Gill AJ, Chou A, Vilain R, Clarkson A, Lui M, Jin R, Tobias V, Samra J, Goldstein D, Smith C, et al.: Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol 2010, 34:636-644.
58. Pollard P.J., Briere J.J., Alam N.A., Barwell J., Barclay E., Wortham N.C., Hunt T., Mitchell M., Olpin S., Moat S.J., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005, 14:2231-2239.
59. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
60. Loenarz C., Schofield C.J. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 2008, 4:152-156.
61. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
62. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, et al.: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
63. Green A, Beer P: Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010, 362:369-370.
64. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, et al.: Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010, 207:339-344.
65. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
66. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
67. Yen K.E., Bittinger M.A., Su S.M., Fantin V.R. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010.